Deutsch English Français

Contact

EP3239178

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...

News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...

Extract from the Register of European Patents

EP About this file: EP3239178

EP3239178 - BINDING MOLECULES TO THE HUMAN OX40 RECEPTOR [Right-click to bookmark this link]
Status	The application has been refused Status updated on 12.03.2021 Database last updated on 19.10.2024
Former	Examination is in progress Status updated on 10.08.2018
Former	Request for examination was made Status updated on 11.05.2018
Former	The application has been published Status updated on 29.09.2017
Most recent event Tooltip	12.03.2021	Refusal of application	published on 14.04.2021 [2021/15]
Applicant(s)	For all designated states Bristol-Myers Squibb Company Route 206 and Province Line Road Princeton, NJ 08540 / US
	For all designated states Pfizer Inc. 235 East 42nd Street New York, NY 10017 / US
	[2017/44]
Inventor(s)	01 / MIN, Jing 15309 Nooning Tree Court Chesterfield, MO 63017 / US
	02 / DEVAUX, Brigitte 320 Duluth Circle Palo Alto, CA 94306 / US
	03 / WU, Yi 1339 Kennedy Drive Milpitas, CA 95035 / US
	04 / TOY, Kristopher 1694 Ambergrove Drive San Jose, CA 95131 / US
	05 / LEBLANC, Heidi N 736 11th Ave Menlo Park, CA 94025-1953 / US
	06 / HUANG, Haichun 4329 Crestwood Street Fremont, CA 94538 / US
	07 / WU, Yanli 9726 Washington Blvd Gaithersburg, MD 20878 / US
	08 / FINN, Rory Francis 976 Sunburst Court Manchester, MO 63021 / US
	09 / THIELE, Barratt Richard 5619 Dantonaire Place Saint Louis, MO 63128 / US
	10 / LIAO, Wei 471 Barbin Street Horsham, PA 19044 / US
	11 / GLADUE, Ronald Paul 83 Rowley Drive Stonington, CT 06378 / US
	12 / RAJPAL, Arvind 150 Granville Way San Francisco, CA 94127-1134 / US
	13 / PARADIS, Timothy Joseph 5 Beaver River Road Richmond, RI 02892 / US
	14 / BRAMS, Peter 2740 11th Avenue Sacremento, CA 95815 / US
	[2017/44]
Representative(s)	Gill Jennings & Every LLP The Broadgate Tower 20 Primrose Street London EC2A 2ES / GB
	[2017/44]
Application number, filing date	17162625.2	11.12.2008
	[2017/44]
Priority number, date	US20070013947P	14.12.2007 Original published format: US 13947 P
	[2017/44]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	EP3239178
	Date:	01.11.2017
	Language:	EN
	[2017/44]
Search report(s)	(Supplementary) European search report - dispatched on:	EP	15.09.2017
Classification	IPC:	C07K16/28, A61P35/00	[2017/44]
	CPC:	C07K16/2878 (EP,US); A61P31/00 (EP); A61P35/00 (EP); A61P35/02 (EP); A61P35/04 (EP); A61P37/04 (EP); (+) A61K2039/505 (EP,US); C07K2317/14 (US); C07K2317/21 (EP,US); C07K2317/565 (US); C07K2317/92 (EP,US) (-)
Designated contracting states	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR [2018/24]
Former [2017/44]	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR
Title	German:	BINDUNG VON MOLEKÜLEN AN DEN HUMANEN OX40-REZEPTOR	[2017/44]
	English:	BINDING MOLECULES TO THE HUMAN OX40 RECEPTOR	[2017/44]
	French:	MOLÉCULES DE LIAISON AU RÉCEPTEUR HUMAIN OX40	[2017/44]
Biological material	This application mentions deposited biological material, check the file for details
Examination procedure	23.03.2017	Date on which the examining division has become responsible
	01.05.2018	Amendment by applicant (claims and/or description)
	01.05.2018	Examination requested [2018/24]
	09.08.2018	Despatch of a communication from the examining division (Time limit: M06)
	18.02.2019	Reply to a communication from the examining division
	21.11.2019	Cancellation of oral proceeding that was planned for 28.11.2019
	28.11.2019	Date of oral proceedings (cancelled)
	03.12.2019	Despatch of communication that the application is refused, reason: substantive examination [2021/15]
	02.03.2021	Application refused, date of legal effect [2021/15]
Appeal following examination	03.02.2020	Appeal received No. T1692/20
	29.01.2021	Invitation to file observations in an appeal (Time limit: M02) [2021/05]
	10.02.2021	Date of receipt of observations in an appeal [2021/07]
	02.03.2021	Result of appeal procedure: appeal of the applicant withdrawn
Parent application(s) Tooltip	EP08862558.7 / EP2242771
	EP12195976.1 / EP2594590
	EP14191564.5 / EP2851374
Fees paid	Renewal fee
	23.03.2017	Renewal fee patent year 03
	23.03.2017	Renewal fee patent year 04
	23.03.2017	Renewal fee patent year 05
	23.03.2017	Renewal fee patent year 06
	23.03.2017	Renewal fee patent year 07
	23.03.2017	Renewal fee patent year 08
	23.03.2017	Renewal fee patent year 09
	12.12.2017	Renewal fee patent year 10
	21.12.2018	Renewal fee patent year 11
	27.12.2019	Renewal fee patent year 12
	Penalty fee
	Additional fee for renewal fee
	31.12.2020	13 M06 Not yet paid
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:	Search	[X]WO9942585 (SISTERS OF PROVIDENCE IN OREGO [US]) [X] 1-16 * page 3, line 10 - line 33 * * example 8 * * claims 1-9 *;
		[X]WO03106498 (CRUCELL HOLLAND BV [NL], et al) [X] 1-16 * page 1, paragraph 2 - page 4, paragraph 1 * * page 22, paragraph L - page 29, paragraph 2 * * page 56, paragraph L - page 58, paragraph 1 * * page 60, paragraph 2 - page 61, paragraph 2 * * examples 1-10 * * claims 1-10,18-28 *;
		[X] - XIE F ET AL, "Characterization and application of two novel monoclonal antibodies against human OX40: costimulation of T cells and expression on tumor as well as normal gland tissues.", TISSUE ANTIGENS APR 2006, (200604), vol. 67, no. 4, ISSN 0001-2815, pages 307 - 317, XP002525127 [X] 1-16 * abstract * * page 310, column l, paragraph l - page 311, column l, paragraph 1 * * page 313, column R, paragraph 2 * DOI: http://dx.doi.org/10.1111/j.1399-0039.2006.00584.x
		[XI] - WEINBERG ANDREW D ET AL, "Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study", JOURNAL OF IMMUNOTHERAPY, LIPPINCOTT WILLIAMS & WILKINS, HAGERSTOWN, MD, US, (20061101), vol. 29, no. 6, ISSN 1524-9557, pages 575 - 585, XP009115398 [X] 1-5 * abstract * * page 576, column r, paragraph 3 * [I] 6-16 DOI: http://dx.doi.org/10.1097/01.cji.0000211319.00031.fc
		[I] - KJAERGAARD J ET AL, "Therapeutic efficacy of OX-40 receptor antibody depends on tumor immunogenicity and anatomic site of tumor growth.", CANCER RESEARCH 1 OCT 2000, (20001001), vol. 60, no. 19, ISSN 0008-5472, pages 5514 - 5521, XP007908325 [I] 1-16 * abstract * * page 5515, column L, paragraph 5 *
		[I] - KJAERGAARD J ET AL, "Augmentation versus inhibition: effects of conjunctional OX-40 receptor monoclonal antibody and IL-2 treatment on adoptive immunotherapy of advanced tumor.", JOURNAL OF IMMUNOLOGY (BALTIMORE, MD. : 1950) 1 DEC 2001, (20011201), vol. 167, no. 11, ISSN 0022-1767, pages 6669 - 6677, XP007908324 [I] 1-16 * abstract * * page 6670, column R, paragraph 4 *
		[A] - BALINT R F ET AL, "Antibody engineering by parsimonious mutagenesis", GENE, ELSEVIER, AMSTERDAM, NL, vol. 137, no. 1, doi:10.1016/0378-1119(93)90258-5, ISSN 0378-1119, (19931227), pages 109 - 118, (19931227), XP023539602 [A] 1-16 * abstract * * page 110, column r, paragraph 2 * DOI: http://dx.doi.org/10.1016/0378-1119(93)90258-5
	by applicant	US191293
		US4399216
		US4510245
		US4634665
		US4740461
		US4912040
		EP0368684
		US4959455
		US4968615
		WO9201047
		US5168062
		US5179017
		WO9306213
		EP0616640
		US5545806
		US5545807
		US5625825
		WO9824884
		US5939598
		WO9942585
		US5994619
		US6075181
		WO0037504
		US6114598
		US6150584
		US6162963
		US6172197
		WO0109187
		US6291158
		WO0243478
		WO02053596
		WO02055106
		WO03002609
		WO03040170
		WO03048731
		US6582915
		US6593081
		WO2004003019
		US6696245
		WO2004058821
		US6765087
		WO2004081026
		WO2004101790
		US6838254
		WO2005035572
		US2006153808
		WO2006079372
		WO2006088639
		WO2006129163
		US2007117809
		WO2007059782
		- SUGAMURA, K.; ISHII, N.; WEINBERG, A, "Therapeutic targeting of the effector T-cellco-stimulatory molecule 0X40", NATURE REV. IMM., (2004), vol. 4, doi:doi:10.1038/nri1371, pages 420 - 431, XP009040312 DOI: http://dx.doi.org/10.1038/nri1371
		- HORI, T, "Roles of 0X40 in the pathogenesis and control of diseases", INTN. J. HEMATOLOGY., (2006), vol. 83, doi:doi:10.1532/IJH97.05151, pages 17 - 22, XP036524124 DOI: http://dx.doi.org/10.1532/IJH97.05151
		- VETTO, J.T. ET AL., "Presence of the T-cell activation marker OX-40 on tumor infiltrating lymphocytes and draining lymph nodes cells from patients with melanoma and head and neck cancers", AM. J. SURG., (1997), vol. 174, doi:doi:10.1016/S0002-9610(97)00139-6, pages 258 - 265, XP002109414 DOI: http://dx.doi.org/10.1016/S0002-9610(97)00139-6
		- WEINBERG, A.D ET AL., "Engagement of the OX-40 receptor in vivo enhances antitumor immunity", J. IMMUNOL., (2000), vol. 164, pages 2160 - 69, XP002224132
		- PETTY, J.K. ET AL., "Survival in human colorectal cancer correlates with expression of the T-cell costimulatory molecule OX-40 (CD134", AM. J. SURG., (2002), vol. 183, doi:doi:10.1016/S0002-9610(02)00831-0, pages 512 - 518, XP055361225 DOI: http://dx.doi.org/10.1016/S0002-9610(02)00831-0
		- CHOTHIA; LESK, J. MOL. BIOL., (1987), vol. 196, pages 901 - 917
		- CHOTHIA ET AL., NATURE, (1989), vol. 342, pages 878 - 883
		- KIPRIYANOV ET AL., HUMAN ANTIBODIES AND HYBRIDOMAS, (1995), vol. 6, pages 93 - 101
		- KIPRIYANOV ET AL., MOL. IMMUNOL., (1994), vol. 31, pages 1047 - 1058
		- HARRIS R. J, J, OF CHROMOTOGRAPHY, (1995), vol. 705, pages 129 - 134
		- WARD, NATURE, (1989), vol. 341, pages 544 - 546
		- BIRD ET AL., SCIENCE, (1988), vol. 242, pages 423 - 426
		- HUSTON ET AL., PROC. NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883
	- SOJAHR, H. T.; BAHL, 0. P., ARCH. BIOCHEM. BIOPHYS., (1987), vol. 259, pages 52 - 57
	- EDGE, A. S. ET AL., ANAL. BIOCHEM., (1981), vol. 118, pages 13 1 - 137
	- THOTAKURA, N. R.; BAHL, O. P., METH. ENZYMOL., (1987), vol. 138, pages 350 - 359
	- HOLLIGER P. ET AL., PROC. NATL. ACAD. SCI. USA, (1993), vol. 90, pages 6444 - 6448
	- POLJAK R. J. ET AL., STRUCTURE, (1994), vol. 2, pages 1121 - 1123
	- KOHLER; MILSTEIN, NATURE, (1975), vol. 256, page 495
	- LONBERG ET AL., NATURE, (1994), vol. 368, pages 856 - 859
	- HARDING, F.; LONBERG, N, ANN. N.Y. ACAD. SCI., (1995), vol. 764, pages 536 - 546
	- FISHWIID, D. ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 845 - 851
	- TOMIZUKA ET AL., PROC. NATL. ACAD. SCI. USA, (2000), vol. 97, pages 722 - 727
	- HUSTON, PROC, NATL. ACAD. SCI. USA, (1988), vol. 85, pages 5879 - 5883
	- MCCAFFERTY, NATURE, (1990), vol. 348, pages 552 - 554
	- MCCAFFERTY ET AL., NATURE, (1990), vol. 348, pages 552 - 554
	- GRIFFITHS ET AL., EMBO J., (1993), vol. 12, pages 725 - 734
	- CHEN ET AL., EMBO J., (1993), vol. 12, pages 821 - 830
	- FISHWILD ET AL., NATURE BIOTECHNOLOGY, (1996), vol. 14, pages 845 - 851
	- ISHIDA ET AL., CLONING AND STEM CELLS, (2002), vol. 4, pages 91 - 102
	- LONBERG ET AL., NATURE, (1994), vol. 368, no. 6474, pages 856 - 859
	- RETH, M. G., NATURE, (1984), vol. 312, no. 29, pages 418 - 42
	- ALT, F. ET AL., CELL, (1981), vol. 27, pages 381 - 390
	WO2008US72640

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.2.25; 34p